רבלוזיל 25 מ"ג - Reblozyl 25 mg
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | B03XA Other antianemic preparations | ||||||||||||||||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||||||||||||||
| צ×רת ××ª× | תת-×¢××¨× - S.C | ||||||||||||||||||
| צ×רת ××× ×× | ×××§× ×××× ×ª ת×××¡× ××ר×ק×, POWDER FOR SOLUTION FOR INJECTION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||||||||||||||
| ×ת×××× | Reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.Reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non-transfusion-dependent beta-thalassaemia | ||||||||||||||||||
| |||||||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
Â
 | ||||||||||||||||||
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ר×××××× 25 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | CELGENE CORPORATION, USA |
| ×©× ××¢× ×ר×ש×× | BRISTOL, MYERS SQUIBB (ISRAEL) LIMITED, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 8/2020. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 18/05/2024 |
ת××× ×ª ×ר×××
השינוי האחרון נעשה בֹ־18 במאי 2024 ב־07:19